Jasper Therapeutics Inc (NASDAQ: JSPR) is -75.40% lower on its value in year-to-date trading and has touched a low of $3.13 and a high of $26.05 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The JSPR stock was last observed hovering at around $5.41 in the last trading session, with the day’s loss setting it -0.15%.
Currently trading at $5.26, the stock is -3.79% and 6.33% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.17 million and changing -2.77% at the moment leaves the stock -56.81% off its SMA200. JSPR registered -78.98% loss for a year compared to 6-month loss of -74.47%.
The stock witnessed a 4.78% gain in the last 1 month and extending the period to 3 months gives it a 1.35%, and is -6.07% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.34% over the week and 4.34% over the month.
Jasper Therapeutics Inc (JSPR) has around 64 employees, a market worth around $79.02M and $0.00M in sales. Distance from 52-week low is 68.05% and -79.81% from its 52-week high. The company has generated returns on investments over the last 12 months (-183.22%).
The EPS is expected to shrink by -7.13% this year
The shares outstanding are 15.02M, and float is at 12.59M with Short Float at 13.71%.
The top institutional shareholder in the company is VELAN CAPITAL INVESTMENT MANAGEMENT LP with over 1.47 million shares valued at $32.55 million. The investor’s holdings represent 9.8216 of the JSPR Shares outstanding. As of 2024-06-30, the second largest holder is SOLEUS CAPITAL MANAGEMENT, L.P. with 1.28 million shares valued at $28.97 million to account for 8.5157 of the shares outstanding. The other top investors are CARLYLE GROUP INC. which holds 1.07 million shares representing 7.1144 and valued at over $24.2 million, while QIMING U.S. VENTURES MANAGEMENT, LLC holds 6.1987 of the shares totaling 0.93 million with a market value of $21.09 million.
Jasper Therapeutics Inc (JSPR) Insider Activity
The most recent transaction is an insider sale by Mahal Jeetinder Singh, the company’s Chief Operating Officer. SEC filings show that Mahal Jeetinder Singh sold 900 shares of the company’s common stock on Dec 12 ’24 at a price of $22.11 per share for a total of $19899.0. Following the sale, the insider now owns 25009.0 shares.
Still, SEC filings show that on Sep 12 ’24, Mahal Jeetinder Singh (Chief Operating Officer) disposed off 900 shares at an average price of $21.23 for $19104.0. The insider now directly holds 25,009 shares of Jasper Therapeutics Inc (JSPR).
